A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

Objective: To evaluate the insulin-only configuration of the iLet® bionic pancreas (BP) using fast-acting insulin aspart (Fiasp®) in adults with type 1 diabetes (T1D).

Why It Was Studied

The primary outcome was HbA1c at 13 weeks.

The BP-F versus SC comparison was considered primary and BP-F versus BP-A/L secondary.

Who Took Part

According to the abstract, 275 adults were involved.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults, older adults and people over 80.

How the Study Was Run

In design terms this was a randomized and multicenter study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

More than one site took part, so the adults came from several places.

The timeline in the abstract includes 13 weeks.

What Was Measured

The primary outcome was HbA1c at 13 weeks.

The BP-F versus SC comparison was considered primary and BP-F versus BP-A/L secondary.

Topics PubMed links to this paper include Bionics, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemia and Hypoglycemic Agents.

The authors tagged it with the keywords Adult, Artificial pancreas, Automated insulin delivery, Bionic pancreas, Evaluation and Fast-acting insulin.

What This Means in Plain Language

The paper is a randomized and multicenter study of Insulin Aspart in 275 adults over 13 weeks.

The publication is from 2022 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page, all human trials.